Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005

被引:85
作者
Rossing, P [1 ]
机构
[1] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
关键词
ACE inhibition; diabetic nephropathy; dual blockade; epidemiology; microalbuminuria; progression of renal disease; progression promoters; type; 1; diabetes;
D O I
10.1007/s00125-005-0077-3
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Diabetic nephropathy is a major problem for patients and health care systems. The costs of treatment remain high. To confront the ongoing challenge, we need to identify individuals at high risk for initiation and progression of this devastating complication. Risk factors include genetic markers; constitutional factors such as low birthweight; haemodynamic factors, including activation of the RAS system and hypertension; metabolic factors such as glycaemia; and additional factors such as urinary AER and smoking. Modifiable risk factors should be treated aggressively. Potential new markers of risk include indices of increased inflammation, changes in coagulation, endothelial dysfunction, growth factors and cytokines. Application of such markers may in time improve risk assessment and allow new treatment targets to be identified. Interventions that aim to achieve strict glycaemic control and blockade of the renin-angiotensin system have been shown to be effective in clinical trials and are feasible in clinical practice. The 'natural history' of diabetic nephropathy can be transformed if these strategies of intensive screening and care are applied, leading both to a lower incidence of diabetic nephropathy and to an improved outcome, with survival exceeding 20 years from onset of overt proteinuria.
引用
收藏
页码:11 / 19
页数:9
相关论文
共 115 条
[1]
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy [J].
Ahmed, SB ;
Hovind, P ;
Parving, HH ;
Rossing, P ;
Price, DA ;
Laffel, LM ;
Lansang, MC ;
Stevanovic, R ;
Fisher, NDL ;
Hollenberg, NK .
DIABETES CARE, 2005, 28 (08) :1988-1994
[2]
THE PREDICTIVE VALUE OF MICROALBUMINURIA IN IDDM - A 5-YEAR FOLLOW-UP-STUDY [J].
ALMDAL, T ;
NORGAARD, K ;
FELDTRASMUSSEN, B ;
DECKERT, T .
DIABETES CARE, 1994, 17 (02) :120-125
[3]
ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
[4]
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes - The CALM II study [J].
Andersen, NH ;
Eiskjer, H ;
Poulsen, PL ;
Hansen, KW ;
Knudsen, ST ;
Helleberg, K ;
Poulsen, SH ;
Mogensen, CE .
DIABETES CARE, 2005, 28 (02) :273-277
[5]
Long-term renoprotective effects of losartan in diabetic nephropathy [J].
Andersen, S ;
Tarnow, L ;
Cambien, F ;
Rossing, P ;
Juhl, TR ;
Deinum, J ;
Parving, HH .
DIABETES CARE, 2003, 26 (05) :1501-1506
[6]
Optimal dose of losartan for renoprotection in diabetic nephropathy [J].
Andersen, S ;
Rossing, P ;
Juhl, TR ;
Deinum, J ;
Parving, HH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (08) :1413-1418
[7]
[Anonymous], 1999, Diabet Med, V16, P918
[8]
Significance of microalbuminuria in long-duration type 1 diabetes [J].
Arun, CS ;
Stoddart, J ;
Mackin, P ;
MacLeod, JM ;
New, JP ;
Marshall, SM .
DIABETES CARE, 2003, 26 (07) :2144-2149
[9]
Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study [J].
Astrup, AS ;
Tarnow, L ;
Rossing, P ;
Pietraszek, L ;
Hansen, PR ;
Parving, HH .
KIDNEY INTERNATIONAL, 2005, 68 (03) :1250-1257
[10]
EPIDEMIOLOGY OF PERSISTENT PROTEINURIA IN TYPE-II DIABETES-MELLITUS - POPULATION-BASED STUDY IN ROCHESTER, MINNESOTA [J].
BALLARD, DJ ;
HUMPHREY, LL ;
MELTON, LJ ;
FROHNERT, PP ;
CHU, CP ;
OFALLON, WM ;
PALUMBO, PJ .
DIABETES, 1988, 37 (04) :405-412